Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 9
- Registration Number
- NCT00183248
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 9
- Registration Number
- NCT00177138
- Locations
- 🇺🇸
University of Minnesota-Fairview, Minneapolis, Minnesota, United States
Alemtuzumab Induction in Islet Transplantation
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 12
- Registration Number
- NCT00175253
- Locations
- 🇨🇦
University of Alberta - Clinical Islet Transplant Program, Edmonton, Alberta, Canada
Islet Transplantation Using Campath-1H and Infliximab Induction
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 12
- Registration Number
- NCT00175266
- Locations
- 🇨🇦
University of Alberta - Clinical Islet Transplant Program, Edmonton, Alberta, Canada
A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 40
- Registration Number
- NCT00166712
- Locations
- 🇺🇸
Northwestern University/Northwestern Memorial Hospital, Chicago, Illinois, United States
Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2007-07-25
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00162851
- Locations
- 🇸🇪
Dept. of Hematology, Karolinska University Hospital, Stockholm, Sweden
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00153985
- Locations
- 🇺🇸
Winship Cancer Institute-Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-04-03
- Target Recruit Count
- 20
- Registration Number
- NCT00157274
- Locations
- 🇵🇪
Schering Peruana S.A., Lima, Peru
Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Dr. Claudia Bösmüller
- Target Recruit Count
- 197
- Registration Number
- NCT00147381
- Locations
- 🇦🇹
University Hospital Innsbruck, Innsbruck, Tyrol, Austria
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2017-02-08
- Target Recruit Count
- 8
- Registration Number
- NCT00143065
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.